A class action lawsuit has been initiated against uniQure N.V., alleging the biopharmaceutical company made materially false and misleading statements regarding its regulatory proceedings. According to the complaint, uniQure misrepresented the status of FDA approval for its Pivotal Study design and provided inaccurate information regarding the timeline for its Biologics License Application (BLA) submission during the period of September 24 through October 31, 2025.
The litigation centers on claims that the company's public statements did not adequately disclose the risks of delays in its regulatory approval process. Investors who purchased uniQure securities during the alleged misrepresentation period and sustained losses may have grounds to participate in the class action. Legal representatives have indicated that interested parties must contact the firm by April 13, 2026, to be considered for appointment as lead plaintiff in the proceeding.
The case represents an effort to hold the company accountable for disclosures related to a key product development timeline. Shareholders who believe they were affected by the statements in question are encouraged to review the full complaint details and consult with legal counsel regarding their potential eligibility and claims.